Asthma & COPD Market Volume Analysis, Segments, Value Share and Key Trends

 

  Asthma is one of the most common diseases afflicting the world's population, as well as a life-threatening condition that affects a patient's regular breathing. It is a chronic condition that causes breathlessness, bronchospasm, and reversible obstruction of airflow by stretching and narrowing the lungs' air passages. "Smoker’s cough" or a chronic cough and breathlessness, Chronic Obstructive Pulmonary Disease (COPD) is defined by a persistent blockage of airflow in the lungs, resulting in abnormal sputum. Cough, breathlessness (shortness of breath) and wheezing, sputum, chest infections, weight loss, tiredness, and ankle swelling are all symptoms of COPD.

  In 2020, global asthma and COPD market is expected to be worth US$ 30,710.2 million, and by 2027, it is expected to be worth US$ 42,608 million. Future growth in the anti-asthmatics and COPD drugs market will be driven by the increased popularity of e-cigarettes/vaping, rising obesity levels, technology, a large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing fat consumption. Side effects associated with respiratory drugs, a reduction in free trade, and stringent regulations are all factors that could slow the market's growth in the future.

  The market for asthma and COPD market is divided into classes based on the severity of the disease. The medication classes used in the treatment of COPD and asthma include short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), combination products, anticholinergics, and others.

  Technological advancements are expected to bring lucrative opportunities to the market. Traditional treatment limitations, such as late-onset of action and low efficacy, are expected to encourage the development of novel targeted drugs, boosting future growth. Sanofi, in collaboration with Regeneron Pharmaceuticals, launched a phase III clinical trial in February 2021 to evaluate the efficacy and safety on the annualized rate of acute moderate-to-severe COPD exacerbations in former smokers with moderate-to-severe COPD (COPD).

AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH are among the major market players.